Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

European Heart Journal

Volumn 36, Issue 17, 2015, Pages 1012-1022

  Stroes, Erik S ^a   Thompson, Paul D ^b   Corsini, Alberto ^c   Vladutiu, Georgirene D ^d   Raal, Frederick J ^e   Ray, Kausik K ^f   Roden, Michael ^g   Stein, Evan ^h   Tokgözoʇlu, Lale ⁱ   Nordestgaard, Børge G ^j   Bruckert, Eric ^k   De Backer, Guy ^l   Krauss, Ronald M ^m   Laufs, Ulrich ⁿ   Santos, Raul D ^o   Hegele, Robert A ^p   Hovingh, G Kees ^q   Leiter, Lawrence A ^r   Mach, Francois ^s   März, Winfried ^t   Newman, Connie B ^u   Wiklund, Olov ^v   Jacobson, Terry A ^w   Catapano, Alberico L ^c   Chapman, M John ^k   Ginsberg, Henry N ^x   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^h Metab and Atherosclerosis Res Ctr   (United States)

ⁱ HACETTEPE UNIVERSITY   (Turkey)

^j GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l GHENT UNIVERSITY   (Belgium)

^m CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

ⁿ SAARLAND UNIVERSITY   (Germany)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p UNIVERSITY OF WESTERN ONTARIO   (Canada)

^q UNIVERSITY OF AMSTERDAM   (Netherlands)

^r ST MICHAEL'S HOSPITAL   (Canada)

^s Cardiology Service   (Switzerland)

^t SYNLAB ACADEMY   (Germany)

^u NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^w EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

Cholesterol; Consensus statement; Lipids; Mitochondrial; Musclesymptoms; Myalgia; Myopathy; Statin; Statin intolerance

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE PROTEIN; NUTRACEUTICAL; PROTEIN INHIBITOR; PSCK9 INHIBITOR; UBIQUINONE; UNCLASSIFIED DRUG; VITAMIN D; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE;

ALTERNATIVE MEDICINE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL ASSESSMENT; CREATINE KINASE BLOOD LEVEL; ENERGY YIELD; GENETIC SUSCEPTIBILITY; HUMAN; MEDICAL SOCIETY; MITOCHONDRION; MUSCLE DISEASE; MYALGIA; MYOPATHY; NONHUMAN; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATIN ASSOCIATED MUSCLE SYMPTOM; VITAMIN SUPPLEMENTATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; CONSENSUS; DIET; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ETIOLOGY; GENETIC PREDISPOSITION; METABOLISM; MUSCLE MITOCHONDRION; MUSCULAR DISEASES; RISK FACTOR;

CHOLESTEROL ESTER TRANSFER PROTEINS; COMPLEMENTARY THERAPIES; CONSENSUS; CREATINE KINASE; DIET; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL DISEASES; MUSCULAR DISEASES; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84927742065     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv043     Document Type: Review

References (120)

1. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818
2. Heart Protection Study Collaborative Group.MRC/BHFHeart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
3. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AMJr, Kastelein JJ, KoenigW, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207
4. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114: 2788-2797
5. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259
6. Dahlö f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
7. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C
8. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, MamdaniMM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013; 346: 2610
9. Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng DS, Pearson GJ, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: CanadianWorking Group Consensus update. Can J Cardiol 2013; 29: 1553-1568
10. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGomaEM. Statins and cognitive function: a systematic review. Ann Intern Med 2013; 159: 688-697
11. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-The PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403-414
12. Buettner C, Rippberger MJ, Smith JK, Leveille SG, Davis RB, Mittleman MA. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012; 125: 176-182
13. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10, 138 current and former statin users. J Clin Lipidol 2012; 6: 208-215
14. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Int Med 2013; 158: 526-534
15. El-Salem K, Ababeneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, Saadeh R, Saydam M. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 2011; 44: 877-881
16. Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, Kokia E. Longterm persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167-2179
17. Jackevicius CA, MamdaniM, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-467
18. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, Stricker B, Mendis S, Hofman A, Mant J, Franco OH. Adherence to cardiovascular therapy: a meta-Analysis of prevalence and clinical consequences. Eur Heart J 2013; 34: 2940-2948
19. Rosenson RS, Baker SK, JacobsonTA, Kopecky SL, Parker BA.Anassessment by the statin muscle safety task force: 2014 update. J Clin Lipidol 2014; 8: 558-571
20. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014; 168: 6-15
21. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21: 464-476
22. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation 2013; 127: 96-103
23. Keech A, Collins S, MacMahon S, Armitage J, Lawson A, Wallendszus K, Fatemian M, Kearney E, Lyon V, Mindell J, Mount J, Painter R, Parish S, Slavin B, Sleight P, Youngman L, Peto R. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-269
24. MRC/BHF Heart Protection Study Collaborative Group. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebocontrolled trial in 20, 536 high-risk people. BMC Clin Pharmacol 2009; 9: 6
25. Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, Cho L. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013; 166: 597-603
26. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-1802
27. Nielsen SF, Nordestgaard BG. Statin use before diabetes and risk of microvascular disease: a nationwide nested matched study. Lancet Diabet Endocrinol 2014; 2: 894-900
28. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-1028
29. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, Zagrebelsky V, Weis S, Shapiro DR, Beere PA, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Additional perspectives on tolerability of long-Term treatment with lovastatin. Am J Cardiol 2001; 87: 1074-1079
30. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790
31. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150: 858-868
32. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003; 17: 265-285
33. Armitage J, Baigent C, Collins R. Misrepresentation of statin safety evidence. Lancet 2014; 384: 1263-1264
34. Ahmad Z. Statin intolerance. Am J Cardiol 2014; 113: 1765-1771
35. Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue QY, Wadelius M, Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CN, Pirmohamed M. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 2014; 96: 470-476
36. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361: 62-72
37. Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother 2013; 47: 398-404
38. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008; 101: 483-485
39. Reddy KJ, Singh M, Batsell RR, Bangit JR, Zaheer MS, John S, Varghese S, Molinella R. Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use. J Clin Hypertens (Greenwich) 2009; 11: 766-768
40. Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J 2013; 34: 1783-1789
41. Cannon CP, IMPROVE-IT Investigators. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. A multicenter, double-blind, randomized study to establish the clinical benefit and safety of Vytorin (ezetimibe/simvastatin tablet) vs simvastatin monotherapy in high-risk subjects presenting with acute coronary syndrome. http://my.americanheart.org/idc/groups/ahamahpublic/@wcm/@sop/@scon/documents/downloadable/ucm-469669.pdf (22 November 2014
42. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR. Efficacy and tolerability of Fluvastatin XL 80 mg alone, ezetimibe alone and the combination of FluvastatinXL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins: a randomized, doubleblind, double-dummy trial. Am J Cardiol 2008; 101: 490-496
43. DavidsonMH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK. Colesevelam hydrochloride (cholestagel): anew, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 1893-1900
44. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia. Drugs 1980; 19: 161-180
45. Knopp RH, Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Goldberg AC, Grundy SM, Lasser NL, Mellies MJ, Palmer RH. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.AmJMed1987; 83: 50-59
46. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse Jr. III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574
47. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861
48. Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, Hou R, Qin Y. Meta-Analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol 2012; 110: 1296-1301
49. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (Niaspan): a long-Term study. Am J Cardiol 1998; 82: 74U-81U
50. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-2267
51. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-1291
52. Anderson JW, Davidson MH, Blonde L, Brown WV, Howard WJ, Ginsberg H, Allgood LD, Weingand KW. Long term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr 2000; 71: 1433-1438
53. Gylling H, Plat J, Turley S, Ginsberg HN, Ellegård L, JessupW, Jones PJ, LütjohannD, MaerzW, Masana L, Silbernagel G, Staels B, Borén J, Catapano AL, De Backer G, Deanfield J, Descamps OS, Kovanen PT, Riccardi G, Tokgözoglu L, Chapman MJ; European Atherosclerosis Society Consensus Panel on Phytosterols. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232: 346-360
54. Jenkins DJ, Jones PJ, Lamarche B, KendallCW, Faulkner D, Cermakova L, Gigleux I, RamprasathV, de Souza R, Ireland C, Patel D, Srichaikul K, Abdulnour S, Bashyam B, Collier C, Hoshizaki S, Josse RG, Leiter LA, Connelly PW, Frohlich J. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA 2011; 306: 831-839
55. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of Coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015; 238: 329-335
56. Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser SP, Lip GYH, Dragan S, Mikhailidis DP, Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Effects of Coenzyme Q10 on statin-induced myopathy: a meta-Analysis of randomized controlled trials. Mayo Clinic Proc 2015; 90: 24-34
57. Bookstaver DA, Burkhalter N, Hatzigeorgiou C. Effect of Coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 2012; 110: 526-529
58. Caso G, Kelly P, McNurlanMA, Lawson WE.Effect of CoenzymeQ10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99: 1409-1412
59. Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporos Int 2012; 13: 187-194
60. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Kees Hovingh G, Farnier M, Moriarty PM, Bittner VA, Lip GY, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group., Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-Associated myalgia -A systematic review and meta-Analysis of 7 studies with 2420 patients. Int J Cardiol 2014; 178C: 111-116
61. Mannarino MR, Ministrini S, Pirro M. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med 2014; 25: 592-599
62. Li Y, Jiang L, Jia Z, XinW, Yang S, Yang Q, Wang L. A meta-Analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 2014; 9: e98611
63. LambertG, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J Lipid Res 2012; 53: 2515-2524
64. Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014; 65: 417-431
65. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 2014; 54: 273-293
66. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2541-2548
67. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308: 2497-2506
68. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Du Y, Pordy R, Gipe D. ODYSSEY ALTERNATIVE: efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-469684.pdf (22 November 2014
69. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS. Efficacy and safety of evolocumab(AMG145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in 4 Phase 2 trials. Eur Heart J 2014; 35: 2249-2259
70. Tavori H, Melone M, Rashid S. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther 2014; 12: 1137-1144
71. ClinicalTrials.gov. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). ClinicalTrials.gov Identifier: NCT01764633. http://clinicaltrials.gov/show/NCT01764633 (10 December 2014
72. ClinicalTrials.gov. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727). ClinicalTrials.gov Identifier: NCT01663402. http://clinicaltrials.gov/ct2/show/NCT01663402 (10 December 2014
73. ClinicalTrials.gov. The Evaluation of Bococizumab (PF-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects (SPIRE-1). ClinicalTrials. gov Identifier: NCT01975376. http://clinicaltrials.gov/ct2/show/NCT01975376 (10 December 2014
74. ClinicalTrials.gov. The Evaluation of Bococizumab (PF-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects (SPIRE-2). ClinicalTrials. gov Identifier: NCT01975389. https://clinicaltrials.gov/ct2/show/NCT01975389 (10 December 2014
75. Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM Jr, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HM. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res 2013; 54: 467-472
76. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306: 2099-2109
77. ClinicalTrials.gov. REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. ClinicalTrials.gov Identifier: NCT01252953. http://clinicaltrials.gov/show/NCT01252953 (10 December 2014
78. ClinicalTrials.gov. A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE). ClinicalTrials.gov Identifier: NCT01687998. http://clinicaltrials.gov/show/NCT01687998 (10 December 2014
79. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014; 24: 4-15
80. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD; Scripps Mercy Clinical Research Center. Statin-Associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-585
81. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, Hoppeler H, Breil F, Draeger A. Association between statin-Associated myopathy and skeletal muscle damage. CMAJ 2009; 181: E11-E18
82. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, Sciacco M, Kaufmann P, DiMauro S. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005; 62: 1709-1712
83. Schick BA, Laaksonen R, Frohlich JJ, Päivä H, Lehtimäki T, Humphries KH, Côté HC. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007; 81: 650-653
84. Stringer HA, Sohi GK, Maguire JA, Côté HC. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J Neurol Sci 2013; 325: 142-147
85. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, Himberg JJ. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77: 851-854
86. Päivä H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, Laakso J, Lehtimäki T, von Bergmann K, Lütjohann D, Laaksonen R. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78: 60-68
87. Wu JS, Buettner C, Smithline H, Ngo LH, Greenman RL. Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications. Muscle Nerve 2011; 43: 76-81
88. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-Associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49: 2231-2237
89. Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117: 3940-3951
90. Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 2009; 587: 219-230
91. Mallinson JE, Constantin-Teodosiu D, Glaves PD, Martin EA, Davies WJ, Westwood FR, Sidaway JE, Greenhaff P. Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents. J Physiol 2012; 590: 6389-6402
92. Araki M, Maeda M, Motojima K. Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate. Eur J Pharmacol 2012; 674: 95-103
93. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 2010; 210: 337-343
94. Curran J, Tang L, Roof SR, Velmurugan S, Millard A, Shonts S, Wang H, Santiago D, Ahmad U, Perryman M, Bers DM, Mohler PJ, Ziolo MT, Shannon TR. Nitric oxidedependent activation of CaMKII increases diastolic sarcoplasmic reticulum calcium release in cardiac myocytes in response to adrenergic stimulation. PLoS One 2014; 9: e87495
95. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001; 20: 591-598
96. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi N, Wortmann RL, Phillips PS. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34: 153-162
97. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2011; 8: 92-103
98. Szendroedi J, Schmid AI, Chmelik M, Toth C, Brehm A, Krssak M, Nowotny P, Wolzt M, WaldhäuslW, Roden M. Insulin-stimulated mitochondrial ATP synthesis occurs independently of intramyocellular lipid accumulation in well-controlled type 2 diabetic humans. PLoS Med 2007; 4: e154
99. Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, Meers GM, Ruebel M, Laughlin MH, Dellsperger KC, Fadel PJ, Thyfault JP. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013; 62: 709-714
100. Obayashi H, Nezu Y, Yokota H, Kiyosawa N, Mori K, Maeda N, Tani Y, Manabe S, Sanbuissho A. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. J Toxicol Sci 2011; 36: 445-452
101. Sidaway J, Wang Y, Marsden AM, Orton TC, Westwood FR, Azuma CT, Scott RC. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica 2009; 39: 90-98
102. Madsen CS, Janovitz E, Zhang R, Nguyen-TranV, Ryan CS, Yin X, Monshizadegan H, Chang M, D'Arienzo C, Scheer S, Setters R, Search D, Chen X, Zhuang S, Kunselman L, Peters A, Harrity T, Apedo A, Huang C, Cuff CA, Kowala MC, Blanar MA, Sun CQ, Robl JA, Stein PD. The guinea pig as a preclinical model for demonstrating the efficacy and safety of statins. J Pharmacol Exp Ther 2008; 324: 576-586
103. Naba H, Kakinuma C, Ohnishi S, Ogihara T. Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats. Biochem Biophys Res Commun 2006; 340: 215-220
104. Zhang P, Verity MA, Reue K. Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. Cell Metab 2014; 20: 267-279
105. Limaye V, Bundell C, Hollingsworth P, Rojana-Udomsart A, Mastaglia F, Blumbergs P, Lester S. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immunemediated myositis and necrotizing myopathy. Muscle Nerve 2014. [Epub ahead of print]
106. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010; 106: 297-306
107. Rodrigues AC. Efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 2010; 6: 621-632
108. Bersot T. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011, p877-905
109. DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 2013; 6: 400-408
110. Gong IY, Kim RB. Impact of genetic variation inOATP transporters to drug disposition and response. Drug Metab Pharmacokinet 2013; 28: 4-18
111. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy-A genome wide study. N Engl J Med 2008; 359: 789-799
112. Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L, Wortmann RL. Genetic risk for malignant hyperthermia in non-Anesthesia-induced myopathies. Molec Genet Metab 2011; 104: 167-173
113. VladutiuGD, Tarnopolsky M, Baker S, Christopher-Stine L, PeltierW, Weisman M, Isackson PJ. Inborn errors of muscle metabolism implicated in risk for statininduced myopathy. Molec Genet Metab 2014; 111: 264-265
114. Baker SK, Vladutiu GD, Peltier WL, Isackson PJ, Tarnopolsky MA. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci 2008; 35: 94-97
115. Ruanttto G, Windemuth A, Wu AH, Kane JP, Malloy MJ, Pullinger CR, Kocherla M, Bogaard K, Gordon BR, Holford TR, GuptaA, Seip RL, Thompson PD. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011; 218: 451-456
116. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, Feng Q, Rieder MJ, Chen YD, Rotter JI, Ridker PM, Hopewell JC, Parish S, Armitage J, Collins R, Wilke RA, Nickerson DA, Stephens M, Krauss RM. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013; 502: 377-380
117. Carr DF, Alfirevic A, Johnson R, Chinoy H, van Staa T, Pirmohamed M.GATMgene variants and statin myopathy risk. Nature 2014; 513: E1
118. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis 2007; 6: 7
119. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol 2014; 78: 684-698
120. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2007; 116: 1971-1996